The Healthy Heart Score (HHS) is an effective tool for identifying the risks of atherosclerotic cardiovascular disease (ASCVD) and can assist in determining counseling for primary prevention. A study, recently published by JAMA, evaluated the performance of the lifestyle-based tool, the HHS, which estimates the risk of early ASCVD events in young adults.
The Healthy Heart Score (HHS) is an effective tool for identifying the risks of atherosclerotic cardiovascular disease (ASCVD) and can assist in determining counseling for primary prevention. A study, recently published by JAMA, evaluated the performance of the lifestyle-based tool, the HHS, which estimates the risk of early ASCVD events in young adults.
The study included 4893 US adults between the ages of 18 and 30 years from the Coronary Artery Risk Development in Young Adults (CARDIA) study. These patients had participated in lifestyle factor measurements from March 25, 1985, through June 7, 1986, and were followed up approximately 27.1 years later.
The HHS was calculated through the consideration of age, smoking status, body mass index (BMI), amount of exercise, alcohol consumption, and diet. A higher overall HHS indicated a greater risk for ASCVD in the study.
At the 27.1 year follow up, 69 ASCVD events occurred in 64 of the women, with 31 being coronary heart disease events and ischemic stroke making up 38 of the events. There were 104 total ASCVD events among 99 men—75 experiencing coronary heart disease events and 29 experiencing ischemic stroke events. These events occurred at 45.9 years old, on average, and most participants showed no signs of clinical ASCVD risk factors during the original examination.
The study emphasized that those who experienced ASCVD events had unhealthier levels of all HHS variables during young adulthood, on average. The HHS was determined to have performed moderately well at estimating the 25-year risk for early ASCVD events.
“Young adulthood is a time of significant change, and improvements in health behaviors during this period have been shown to reduce the likelihood of having intermediate markers of atherosclerosis in the CARDIA28 and other longitudinal cohorts,” the authors wrote.
The HHS is noted to be a strong indicator because of its reliance on lifestyle factors that can be self-reported. A physician can have a patient complete the HHS, which can help lead discussion on how to modify behavior to improve cardiovascular health in efforts to prevent ASCVD. The researchers acknowledged the minimal awareness and attention of cardiovascular risks among young people and expressed hope that the HHS can be used to change that.
“Whether and how a risk estimation tool such as the HHS can be used to motivate young persons to seek regular primary care and lower their risk for ASCVD through behavior change remains an area for future research,” the authors concluded.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More